Monday, February 25, 2019 11:41:31 PM
"KALY rumor alert
I have just heard that GW Pharma is in ongoing discussions with Kalytera.
I’ve been told that GW Pharma will look for minority stake in KALY with options in exchange for ongoing guidance as well as capital to advance phase 3 trials.
Options would be exercised upon the successful completion of phase 3 which would give GW a majority stake and overall control.
I imagine this would garner a lot of interest in Kalytera."
Dr. Raphael Mechoulam, Ph.D., is the Co-Chair of the Scientific Advisory Board for Kalytera and also has a relationship with GW Pharma.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM